Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience

摘要

Background The expiry of patents for costly biologics is creating new momentum on the pharmaceutical market for biosimilars (copies of off-patent biologics) and paving the way for their development. However, little is known about the competitiveness of biosimilars versus their originators and other biologics belonging to the same therapeutic class.